MedPath

Therapeutic effect of Peg-IFN therapy combined with RBV and telaprevir(TVR) on patients with chronic hepatitis C

Not Applicable
Conditions
Chronic hepatitis C
Registration Number
JPRN-UMIN000013743
Lead Sponsor
Division of digestive and lifestyle disease, Kagoshima university graduate school of medical and dental sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who did not fulfill the criteria to receive the approved Peg-IFN-alpha2b/RBV/telaprevir treatment

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
sustained virologic response rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath